CALGARY, AB, May 31, 2021 /PRNewswire/ – Health Logic Interactive Inc. («Health Logic» or the «Company«) (TSXV.CHIP.H) (OTCPK: CHYPF), is pleased to announce the establishment of a professorship in lab-on-chip innovations at a leading Canadian University. (the «Professorship«). The Professorship will advance a quality research program focused on the innovation and development of lab-on-chip technologies.
The Professorship will take place over the next five years and will aim to facilitate academic-industrial collaborations and partnerships to translate lab research into real world applications. This research will be focused on developing lab-on-chip technologies for point-of-care disease diagnosis and lab-on-chip platforms for therapeutic applications such as drug discovery and regenerative medicine.
«The upcoming establishment of the Professorship between Health Logic Interactive and in a post secondary faculty of science setting is a major milestone in industry and academic collaboration for lab-on-chip technologies. This Professorship will provide the necessary funding to further lab-on-chip progression, which we expect to facilitate future development and commercialization opportunities» stated David Barthel, Chief Executive Officer of Health Logic.
The Professorship will be funded by Health Logic through an annual $50,000 contribution to the University for a period of five years.
Health Logic Announces Option Grant
The Company reports that its board of directors has approved the grant of an aggregate of 1,950,000 stock options to certain directors, employees and consultants (the «Options») pursuant to the terms of the Company’s stock option plan. The Options have an exercise price of $0.20 and expire on May 31, 2024.
About the Company
Health Logic Interactive, through its wholly owned operating subsidiary My Health Logic, is developing and commercializing consumer focused handheld point-of-care diagnostic devices that connect to patient’s smartphones and digital continued care platforms. The Company plans to use their patent pending lab-on-chip technology to provide rapid results and facilitate the transfer of that data from the diagnostic device to the patient’s smartphone. The Company expects this data collection will allow it to better assess patient risk profiles and provide better patient outcomes. Our mission is to empower people with the ability to get early detection anytime, anywhere with actionable digital management for chronic kidney disease. For more information visit us at: www.healthlogicinteractive.com
Further information regarding Health Logic Interactive Inc. and its disclosure documents are available on SEDAR at www.sedar.com.
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this press release constitute «forward-looking statements». All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the duration of the Professorship, the ability of the Professorship to facilitate academic-industrial collaborations and partnerships to translate lab research into real world applications, expectations regarding the Professorship facilitating development and commercialization opportunities for lab-on-chip technology, and the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words «believe», «expect», «aim», «intend», «plan», «continue», «will», «may», «would», «anticipate», «estimate», «forecast», «predict», «project», «seek», «should» or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s Management’s Discussion and Analysis for the year ended December 31, 2020. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law.
View original content to download multimedia:http://www.prnewswire.com/news-releases/health-logic-interactive-announces-the-establishment-of-professorship-in-lab-on-chip-innovations-and-grant-of-options-301302495.html
SOURCE Health Logic Interactive Inc.